Cyclacel Pharmaceuticals (CYCC) Competitors $0.27 -0.01 (-3.65%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$0.27 0.00 (0.00%) As of 04/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. OMGA, HOTH, CYCN, APLM, DWTX, BTAI, MYNZ, ALZN, KLTO, and AEONShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Omega Therapeutics (OMGA), Hoth Therapeutics (HOTH), Cyclerion Therapeutics (CYCN), Apollomics (APLM), Dogwood Therapeutics (DWTX), BioXcel Therapeutics (BTAI), Mainz Biomed (MYNZ), Alzamend Neuro (ALZN), Klotho Neurosciences (KLTO), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Omega Therapeutics Hoth Therapeutics Cyclerion Therapeutics Apollomics Dogwood Therapeutics BioXcel Therapeutics Mainz Biomed Alzamend Neuro Klotho Neurosciences AEON Biopharma Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Do analysts recommend CYCC or OMGA? Cyclacel Pharmaceuticals presently has a consensus price target of $11.00, indicating a potential upside of 3,989.22%. Omega Therapeutics has a consensus price target of $9.20, indicating a potential upside of 7,260.00%. Given Omega Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Omega Therapeutics is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Omega Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk and volatility, CYCC or OMGA? Cyclacel Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Does the MarketBeat Community prefer CYCC or OMGA? Cyclacel Pharmaceuticals received 159 more outperform votes than Omega Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Omega Therapeutics an outperform vote while only 45.39% of users gave Cyclacel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCyclacel PharmaceuticalsOutperform Votes18745.39% Underperform Votes22554.61% Omega TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Which has higher earnings and valuation, CYCC or OMGA? Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Omega Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclacel Pharmaceuticals$74K22.85-$22.56M-$9.40-0.03Omega Therapeutics$8.10M0.85-$97.43M-$1.33-0.09 Is CYCC or OMGA more profitable? Omega Therapeutics has a net margin of -902.93% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. Omega Therapeutics' return on equity of -213.13% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals-18,150.00% -1,901.11% -188.23% Omega Therapeutics -902.93%-213.13%-41.24% Do institutionals & insiders have more ownership in CYCC or OMGA? 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are owned by institutional investors. 24.0% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Omega Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to CYCC or OMGA? In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Omega Therapeutics. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for Omega Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Omega Therapeutics' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Cyclacel Pharmaceuticals Positive Omega Therapeutics Neutral SummaryOmega Therapeutics beats Cyclacel Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Remove Ads Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69M$6.75B$5.54B$7.86BDividend YieldN/A2.81%5.35%4.06%P/E Ratio-0.037.0923.4418.67Price / Sales22.85199.59367.8787.31Price / CashN/A65.6738.1634.64Price / Book0.475.966.634.09Net Income-$22.56M$142.11M$3.20B$246.93M7 Day Performance-11.63%-7.60%-5.00%-3.16%1 Month Performance-18.85%-12.56%-1.57%-6.74%1 Year Performance-87.31%-13.53%8.72%-0.49% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals3.1757 of 5 stars$0.27-3.7%$11.00+3,989.2%-86.9%$1.69M$74,000.00-0.0314Analyst ForecastNews CoverageOMGAOmega Therapeutics1.9412 of 5 stars$0.13-21.8%$9.20+7,260.0%-96.1%$6.92M$8.10M-0.09120Gap UpHOTHHoth Therapeutics2.9202 of 5 stars$1.00-2.9%$4.00+300.0%-31.4%$6.90MN/A-0.764Earnings ReportAnalyst ForecastCYCNCyclerion Therapeutics2.3189 of 5 stars$2.50-2.7%N/A-18.6%$6.78M$2M-2.0530Short Interest ↓Gap UpAPLMApollomics2.5592 of 5 stars$6.20-18.5%$200.00+3,125.8%-89.8%$6.74M$1.22M0.0045News CoverageGap UpHigh Trading VolumeDWTXDogwood TherapeuticsN/A$5.01-11.2%N/AN/A$6.67MN/A-0.765Earnings ReportGap UpBTAIBioXcel Therapeutics4.6701 of 5 stars$2.03-4.2%$42.60+1,998.5%-95.7%$6.51M$2.28M-0.0690Earnings ReportGap DownMYNZMainz Biomed2.2261 of 5 stars$3.21-10.3%$14.00+336.1%-92.8%$6.42M$917,203.00-0.0530Upcoming EarningsNews CoverageHigh Trading VolumeALZNAlzamend Neuro3.4534 of 5 stars$0.95-10.5%$20.00+2,009.0%-88.8%$6.26MN/A0.004KLTOKlotho NeurosciencesN/A$0.23+1.1%N/AN/A$6.16MN/A0.00N/AEarnings ReportGap DownAEONAEON Biopharma2.2459 of 5 stars$0.58-2.3%$360.00+62,022.5%-99.9%$6.10MN/A3.225Upcoming EarningsGap Down Remove Ads Related Companies and Tools Related Companies Omega Therapeutics Competitors Hoth Therapeutics Competitors Cyclerion Therapeutics Competitors Apollomics Competitors Dogwood Therapeutics Competitors BioXcel Therapeutics Competitors Mainz Biomed Competitors Alzamend Neuro Competitors Klotho Neurosciences Competitors AEON Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
